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Abstract   17 
Background:  18 
Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have 19 
impaired health-related quality of life (HRQoL), which is improved significantly for many by 20 
treatment with methotrexate (MTX). However, a significant proportion of CYP experience 21 
difficulties in taking MTX, which may reduce its potential benefits for HRQoL.  The aim of 22 
this research was to examine how CYP with JIA perceive MTX treatment and how this 23 
relates to HRQoL. 24 
Methods: CYP aged 8-16 years taking MTX for JIA completed an adapted Parent Adherence 25 
Report Questionnaire, which contains 100mm visual analogue scales, to assess difficulty 26 
taking MTX, adherence, frequency of negative reactions and helpfulness of MTX. They also 27 
completed the Pediatric Quality of Life Inventory (PedsQL) Generic and Rheumatology 28 
scales.  We collected data on age, gender, JIA course, disease duration, MTX duration of use, 29 
route and dose. Number of inflamed and limited joints were indicators of disease severity. 30 
Results: 116 CYP participated. Most considered MTX helpful (median 87; interquartile 31 
range (IQR) 50.75–98) and reported adherence was high (median 98; IQR 90–100). There 32 
was greater variability on scores for difficulty (median 22; IQR 2–69) and frequency of 33 
negative reactions (median 14.5; IQR 1.25–80).  Mean (S.D.) scores on the PedsQL Physical 34 
and Psychosocial subscales were 71.63 (24.02) and 71.78 (19.59) respectively, indicating 35 
poorer HRQoL than that reported by healthy children.   After controlling for demographic 36 
and disease variables, poorer physical HRQoL was significantly accounted for by greater 37 
difficulty in taking MTX. Poorer psychosocial HRQoL was significantly accounted for by 38 
subcutaneous MTX administration, a lower rating of MTX helpfulness and a greater reported 39 
difficulty in taking MTX. 40 
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Conclusions: Taking MTX for JIA was viewed as helpful by most CYP but HRQoL was 41 
poorer in those who reported greater difficulty in taking MTX. 42 
 43 
Keywords: Juvenile idiopathic arthritis, methotrexate, quality of life  44 
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BACKGROUND: 45 
Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have 46 
impaired health-related quality of life (HRQoL), particularly on measures of the physical 47 
domain [1,2]. Although this is improved significantly for many CYP by treatment with 48 
methotrexate (MTX) [3] and biologic therapies [4], HRQoL can remain suboptimal [5]. 49 
Higher pain scores and poorer physical function are important predictors of poorer HRQoL in 50 
JIA [6] but variability in HRQoL is not explained purely by these factors [7]. For example, 51 
Seid et al [5] found that many CYP with no or mild symptoms still report impaired HRQoL.  52 
 53 
A factor that may influence HRQoL in JIA is how CYP experience their treatment.  Although 54 
MTX has been found to improve HRQoL in JIA [3], CYP may experience side effects such 55 
as nausea and vomiting and procedural distress [8,9]. Approximately half of CYP who take 56 
MTX for JIA are reported to experience difficulties. We have previously reported proxy data 57 
from mothers of CYP with JIA which found that feeling sick after taking MTX and anxiety 58 
about injections were related to poorer HRQoL [9].  Such proxy reports are essential in child 59 
health, particularly in relation to younger children, but given the differences found between 60 
patient and proxy reports on other measures [10-12], CYP’s own reports of their experiences 61 
of taking medication for JIA are also needed. 62 
 63 
We are aware of two studies in JIA that have examined the relationship between CYP’s 64 
views about their treatment and their HRQoL. Seid et al [7] found a relationship between 65 
greater self-reported treatment problems assessed with the PedsQL Rheumatology Module 66 
[2] and poorer physical and psychosocial HRQoL.  A study which examined HRQoL in JIA 67 
using self-reports from CYP aged 8 years and over, identified ‘subjective burden of 68 
medication use’ as a predictor of psychosocial HRQoL in JIA [13]. Neither of these studies 69 
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asked specifically about MTX and we are not aware of any research that has examined CYP’s 70 
own reports of taking MTX and how this impacts on their HRQoL.   The aim of this study 71 
was to examine how CYP with JIA perceive their MTX treatment and how this relates to 72 
their HRQoL. 73 
 74 
 75 
METHODS 76 
Design 77 
A cross-sectional design was used. Data were collected as part of the Childhood Arthritis 78 
Response to Medication Study (CHARMS), which investigates factors that influence 79 
response to MTX or anti-TNF treatment for JIA. This study examines genetic, immunological 80 
and psychological aspects of response to medication and recruits CYP who are about to start 81 
taking methotrexate (MTX) or anti-TNF, are taking MTX at the time of recruitment or have 82 
taken MTX in the past. The study methodology has been described in detail elsewhere [9]. 83 
 84 
Participants 85 
Participants were recruited from Great Ormond Street Hospital for Children and the 86 
Adolescent Rheumatology service at University College Hospital, London, UK between May 87 
2006 and May 2008. Patients were eligible to take part in the CHARMS study if they had a 88 
diagnosis of JIA defined by International League of Associations for Rheumatology (ILAR) 89 
criteria [14]. Although CHARMS recruits patients of any age, only patients aged 8 years and 90 
over completed questionnaires about their experience of MTX.  Not all CYP in the study 91 
were still taking MTX at the time the study questionnaires were completed. As some CYP 92 
may have ceased taking MTX because they were well but others may have ceased due to 93 
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intolerance, this analysis is restricted to those CYP who were taking MTX at the time of 94 
questionnaire completion to help ensure a more homogeneous sample. 95 
 96 
Procedures 97 
Parents were approached to take part in the CHARMS study at a routine out-patient 98 
appointment. Written informed consent was obtained from at least one parent and age-99 
appropriate written assent was obtained from the patient. CYP completed the questionnaires 100 
described below during waiting time in the clinic. They were given the option to complete the 101 
questionnaires independently or for the researcher to read through the questions for them. The 102 
researcher was also available to answer any queries from CYP who chose to complete the 103 
questionnaires independently. Parents did not assist CYP with questionnaire completion.     104 
 105 
Ethics, consent and permissions 106 
The study had full ethical approval from the Institute of Child Health/GOSH Local Research 107 
Ethics Committee, reference 05/Q0508/95. All participants gave full, informed written 108 
consent (parental consent and age appropriate child/young person assent). The study 109 
conforms to the principles outlined in the Declaration of Helsinki. 110 
 111 
Measures 112 
Participants completed the following questionnaires: 113 
 Views about MTX were assessed by adapting the Parent Adherence Report 114 
Questionnaire (PARQ)[15] so that the questions were addressed to the CYP instead of 115 
the parent. CYP indicated on a 100mm horizontal VAS i) their level of difficulty in 116 
taking MTX with endpoints very easy/very hard; ii) how often they take MTX as 117 
prescribed with endpoints never/always; iii) negative reactions such as crying in response 118 
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to taking MTX with endpoints never/always and iv) their opinion of the helpfulness of 119 
MTX for their arthritis with endpoints not helpful/very helpful. A mean of questions i) – 120 
iii) is calculated to provide an ‘ability to take’ score. Higher scores represent greater 121 
perceived ability to take and greater perceived helpfulness. 122 
 HRQoL was assessed using the Pediatric Quality of Life Inventory (PedsQL) Generic 123 
and Rheumatology scales [2]. The generic scale provides physical and psychosocial 124 
composite scores. The rheumatology scale has 5 subscales: pain and hurt; daily activities; 125 
treatment; worry; communication.  The composite and subscale scores are each 126 
transformed to 0–100 scores as specified by Varni et al (2002)[2], where a higher score 127 
represents better HRQoL. 128 
 We also collected data on the child’s age, gender, JIA type according to ILAR criteria 129 
[14]  (systemic, oligoarticular  persistent, oligoarticular extended, polyarticular RF-, 130 
polyarticular RF+, psoriatic, enthesitis-related arthritis (ERA), undifferentiated) disease 131 
duration, MTX duration of use, route and dose. The number of inflamed/active and 132 
limited joints was recorded as indicators of current disease activity. 133 
 134 
Statistical analysis 135 
Statistical analysis was performed in IBM SPSS Statistics 22.   136 
Medians and interquartile ranges (IQR) were calculated for scores on the PARQ. To examine 137 
the hypothesis that CYP’s views of MTX would account for some of the variance in HRQoL 138 
measured with the PedsQL, the relationship between variables was examined initially by 139 
correlations (Pearson r correlations for continuous variables, Spearman’s rho (rs) for ordinal 140 
variables). In the case of categorical independent variables (e.g. gender), differences in 141 
HRQoL between categories were examined by t-test or analysis of variance (ANOVA), as 142 
applicable. As expected, we recruited small numbers of CYP with the lower prevalence JIA 143 
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types (psoriatic = 6; ERA = 7; undifferentiated = 2); therefore we classified participants into 144 
whether they had an oligoarticular or polyarticular course, that is the number of joints that 145 
had been involved up to the time of the study (4 or less, more than 4 respectively). 146 
To examine which variables accounted for most variance in HRQoL, all significant variables 147 
identified from the univariate analyses were included in hierarchical multiple regressions 148 
using enter method and a level of p <.05 as an entry criterion. 149 
 150 
Two regression analyses were performed, one for the Physical and one for the Psychosocial 151 
summary scales of the Generic PedsQL. The independent variables were entered into the 152 
regression in blocks in the following order: 1. Demographic variables; 2. Disease variables; 3. 153 
MTX-related variables. This order was used because it enables examination to be made as to 154 
whether experience of MTX added to the explanation of quality of life once disease severity 155 
had been taken into account.  156 
 157 
RESULTS  158 
116 CYP who were taking MTX at the time of study recruitment completed the study 159 
questionnaires. Sample characteristics are shown in Table 1. As expected in JIA, the majority 160 
of CYP were female, and for most, their JIA had taken a polyarticular course, affecting 5 or 161 
more joints. A small majority of CYP (54.3%) were taking MTX subcutaneously at time of 162 
assessment.  163 
 164 
CYP’s views about MTX are shown in Figure 1, which reports the median and inter quartile 165 
range (IQR) scores on the PARQ. Self-reported adherence was very high among most CYP, 166 
with a median (IQR) of 98 (90 - 100) on the 100mm scale, however 20 (17.4%) scored below 167 
80, and of these, 9 (7.8%) scored below 50. Scores on the other items of the PARQ showed 168 
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greater variability. A quarter of CYP scored 69 or above on the 100mm scale for level of 169 
difficulty in taking MTX and 80 or above on the 100mm scale for frequency of negative 170 
reactions to MTX. Most CYP rated MTX as helpful with half scoring 87 or above on level of 171 
helpfulness however a quarter scored on or below the midpoint of the scale.  172 
 173 
Scores on the PedsQL Generic Scale and Rheumatology Module are shown in Table 2. Mean 174 
scores on the Rheumatology Module and Physical and Psychosocial subscales were similar to 175 
those recorded by the scale's developers in children with JIA [2]. Scores were poorer than 176 
those reported by a healthy UK sample, aged 8-18 years, of 88.51 (11.62) and 81.84 (13.21) 177 
respectively [16].    178 
 179 
In univariate analysis, the independent variables that were associated with better Physical 180 
HRQoL were: male gender (t=2.12, df=114, p<0.05); fewer active joints (rs = -0.22, p<0.05); 181 
greater perceived ability to take MTX (r=0.38, p<0.005) and greater perceived helpfulness of 182 
MTX (r=0.30, p=0.001). The independent variables that were associated with better 183 
Psychosocial HRQoL were: fewer active joints (rs = -0.23, p<0.05); oral administration of 184 
MTX (t=2.27, df=113, p<0.05), greater perceived ability to take MTX (r=0.38, p<0.005) and 185 
greater perceived helpfulness of MTX (r=0.27, p<0.005). 186 
 187 
Multivariate analyses of the relation between experiences of MTX and physical and 188 
psychosocial HRQoL are shown in Table 3. CYP’s perceptions of MTX made a small but 189 
statistically significant contribution to explaining variability in HRQoL. MTX-related 190 
variables explained an additional 9% and 16% respectively in physical and psychosocial 191 
HRQoL after controlling for gender and disease activity, as shown by the change in 192 
cumulative adjusted R2 in Table 3. After controlling for demographic and disease variables, 193 
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poorer physical HRQoL was significantly accounted for by greater reported difficulty in 194 
taking MTX. Poorer psychosocial HRQoL was significantly accounted for by subcutaneous 195 
MTX administration, a lower rating of MTX helpfulness and a greater reported difficulty in 196 
taking MTX.  197 
 198 
 199 
DISCUSSION 200 
This is the first study of which we are aware that has reported CYP’s views about taking 201 
MTX for JIA in relation to their HRQoL. In the multiple regression analyses MTX-related 202 
variables made an independent contribution to explaining variance in physical and 203 
psychosocial HRQoL after controlling for demographic and disease-related variables. 204 
Physical HRQoL was poorer in those who reported greater difficulty in taking MTX. 205 
Psychosocial HRQoL was poorer in those who: took MTX subcutaneously rather than orally; 206 
reported a greater level of difficulty in taking MTX and reported a lower level of helpfulness 207 
of MTX. Our findings concur with those of Seid et al 2014 [7] and Haverman et al 2012 [13], 208 
which found that self-reported problems with treatment were related to poorer HRQoL. The 209 
current study found that MTX-related factors were important in explaining both physical and 210 
psychological HRQoL as measured by the PedsQL. 211 
 212 
We have previously reported findings from the mothers of CYP in the CHARMS study [9].  213 
Approximately half of CYP were reported by their mothers to have experienced MTX side 214 
effects and/or procedural anxiety regarding injections or blood tests. The child assessment we 215 
report in this paper used a simpler, less detailed measure of MTX-related difficulties, so the 216 
results are not directly comparable but the finding of a relationship between problems taking 217 
MTX and poorer HRQoL is consistent across the respondents.  218 
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 219 
Receiving MTX to treat JIA has been shown to have a beneficial effect on CYP’s HRQoL 220 
[3], however those CYP who experience difficulty in taking MTX may not gain the full 221 
benefit. This study has shown that although most CYP rated MTX as helpful and reported 222 
high adherence, a significant minority report difficulties taking MTX and these difficulties 223 
were associated with poorer HRQoL. Clinicians who ask directly about CYPs' experiences of 224 
taking MTX may be able to further enhance the HRQoL of their patients by offering 225 
treatments to help address these difficulties.  226 
 227 
Psychosocial HRQoL was poorer in CYP taking MTX by subcutaneous rather than oral route. 228 
The data for this study were collected before the introduction of the Metoject pen.  It would 229 
be of interest to examine whether use of the pen has an impact on pain and/or anxiety and any 230 
consequent impact on HRQoL.    231 
 232 
The study has several limitations. As the study is cross-sectional, the direction of causation is 233 
unclear therefore it is possible that those children with poorer HRQoL have a generally more 234 
negative outlook and perceive MTX more negatively. We have however controlled for 235 
disease activity in the analysis (see Table 3) which indicates that experience of MTX is an 236 
independent predictor of HRQoL after taking disease activity into account i.e. it is not the 237 
case that the findings are explained simply by CYP with more active joints perceiving MTX 238 
more negatively.  239 
 240 
The study reports HRQoL at a single time-point in those CYP currently taking MTX. 241 
Although the CHARMS study included CYP who were no longer taking MTX, the study was 242 
not examining reasons for stopping MTX and therefore this information was not recorded. It 243 
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is possible that HRQoL would have varied in those CYP who stopped MTX due to 244 
intolerance or remission but we were unable to examine these differences. We therefore 245 
limited the analyses in this paper to CYP currently taking MTX. It would be informative to 246 
examine CYPs' experiences of taking MTX and HRQoL over time from when they first take 247 
the medication. 248 
 249 
As the study respondents are CYP, it is limited to those aged eight years and over. However, 250 
a strength of the CHARMS study is that we collected data from both parents and CYP so our 251 
related publication reporting mothers’ views was able to include proxy reports for younger 252 
children. A limitation of using a VAS to measure participants’ views about MTX is that it is 253 
not clear what cut-off scores on the 100mm scales should be considered to signify, for 254 
example,  mild, moderate and severe problems in taking MTX and therefore what percentage 255 
of CYP would fall into each category. The CYP in this study were already being treated with 256 
MTX for varying durations when they were recruited therefore it was not possible to control 257 
for level of response to MTX in our analysis. We did, however, include an indicator of 258 
disease severity in the number of active and limited joints. 259 
 260 
CONCLUSIONS 261 
In conclusion, this analysis of CYP’s views about and experience of taking MTX supports the 262 
findings from our reports of mothers of CYP with JIA that MTX is viewed as helpful by most 263 
CYP but HRQoL is poorer in those who report greater difficulty in taking MTX. 264 
 265 
  266 
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Figure 1. Views about methotrexate 362 
 363 
Figure Description: 364 
Figure 1 shows boxplots of scores on the adapted PARQ measure. 365 
 366 
Figure Legend: 367 
Scale 0 – 100, higher score = greater perceived difficulty/ adherence/ negative reactions/ 368 
helpfulness/ability to take. 369 
The dark lines in the middle of boxes show the median. The bottom and top of the boxes 370 
show the 25th and 75th percentile respectively. The T-bars show the minimum and maximum 371 
scores. Circles show outliers. 372 
*The Ability score is a combination of the Difficulty (reversed), Adherence and Negative 373 
reactions (reversed) scores. 374 
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Table 1. Sample characteristics 375 
n  116 
Gender, n (%) female 77 (66.4) 
Age in years when questionnaire data completed, mean (S.D.)  11.9 (2.2) 
JIA course, n (%) 
   systemic 
   oligoarticular  
   polyarticular 
 
14 (12.1) 
11   (9.5) 
91 (78.4) 
Disease duration in years, mean (S.D.)    5.5 (3.4) 
Current disease severity, median, range,  (IQR) 
   Number of active joints (data for n = 111) 
   Number of limited joints (data  for n = 108)  
 
0, 0-10, (0-2) 
1, 0-32, (0-3) 
Duration of MTX use in years, median (IQR) 2 (1-5) 
MTX current route 
   Oral, n (%) 
   Subcutaneous, n (%) 
 
53 (45.7) 
63 (54.3) 
Current MTX dose in mg/m2/week, median (IQR) 15 (12.5 – 20.0) 
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Table 2. Participant scores on the Generic Core Scales and Rheumatology Module of 377 
the Pediatric Quality of Life Inventory (PedsQL) 378 
PedsQL, Generic Scale, mean (S.D.) * 
Physical 
Psychosocial 
 
71.63 (24.02) 
71.78 (19.59) 
PedsQL, Rheumatology Module, mean (S.D.) * 
Pain and hurt 
Daily activities 
Treatment 
Worry 
Communication 
 
65.80 (25.94) 
85.91 (19.77) 
69.51 (21.65) 
67.17 (24.16) 
64.51 (28.97) 
* scale 0 – 100, higher score = better HRQoL379 
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Table 3. Multiple regression analyses of variables related to health-related quality of life 380 
 PedsQL  Physical PedsQL Psychosocial 
Variables
 
     β
 
 t
 
Cumulative 
Adjusted 
R2 
    β
 
t
 
Cumulative 
Adjusted R2 
Demographics:
 
Gender
 
 
 -0.149 
 
 -1.645 
 0.03  
- 
 
- 
  
Disease activity:
 
Active joints
 
 
-0.110 
 
-1.195 
 0.05  
-0.126 
 
-1.422 
  0.03 
MTX: 
 
Subcutaneous route
 
PARQ Ability to take
 
PARQ Helpfulness 
 
- 
 0.256 
 0.159 
 
- 
2.688** 
 1.732 
 0.14  
-0.197 
 0.270 
 0.217 
 
-2.216* 
2.912** 
 2.408* 
  0.19 
*p<0.05, **p<0.01 381 
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